Urologic Diseases  >>  Soliris (eculizumab)  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Soliris (eculizumab) / AstraZeneca
NCT01770951: A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

Completed
N/A
30
Europe, Canada, US
Alexion
Atypical Hemolytic Uremic Syndrome (aHUS)
11/10
11/10
NCT01755429: To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS Patients

Completed
N/A
2
Japan
Alexion Pharmaceuticals
ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)
05/12
07/12
NCT01412047: Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study

Completed
N/A
75
US, Europe, RoW
Alexion Pharmaceuticals
Paroxysmal Nocturnal Hemoglobinuria, PNH
06/13
06/13
EMBRACE, NCT00438789: The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol

Approved for marketing
N/A
US
eculizumab
Alexion Pharmaceuticals
Hemoglobinuria, Paroxysmal
 
 
NCT01522170: aHUS Observational Long Term Follow-Up

Terminated
N/A
94
US, Canada, Europe, RoW
Alexion Pharmaceuticals
Atypical Hemolytic Uremic Syndrome
01/17
01/17

Download Options